Varicella Zoster Virus AB (IgM) Test · Blood

If you have ever had chickenpox, the virus that caused it never left your body. Varicella zoster virus (VZV) stays dormant in your nerve cells for life, and it can reawaken decades later as shingles. VZV IgM (immunoglobulin M) is the first antibody your immune system fires off when VZV becomes active, whether from a brand new infection or a flare of the virus you have been carrying since childhood.

This test is most useful when your doctor suspects active VZV but needs confirmation, or when you develop unexplained nerve pain, facial paralysis, or a suspicious rash. It is not a routine screening test for healthy adults, but it fills a specific diagnostic gap that standard blood panels cannot touch.

What VZV IgM Actually Measures

IgM is the largest antibody your body makes, and it is always the first to appear when your immune system encounters a threat. Your B cells (the white blood cells responsible for producing antibodies) begin releasing VZV-specific IgM about 6 to 10 days after a VZV rash appears. Levels peak around one month, then gradually decline and are usually undetectable by about 10 weeks.

IgM makes up roughly 10% of your total antibodies and stays confined to your blood and lymph. It works like a rapid-response team: fast to arrive, quick to leave. By contrast, VZV IgG (immunoglobulin G), the other main antibody measured in VZV testing, makes up about 80% of total antibodies, circulates throughout your body, and persists for years or even a lifetime after infection.

The Sensitivity Problem

Here is the single most important limitation of this test: VZV IgM is only detectable in about 35 to 37% of confirmed VZV infections when measured by standard ELISA (a common antibody detection method). That means roughly two out of three people with proven active VZV will test negative for IgM. A negative result does not rule out VZV.

An older study using a different technique, immunofluorescence (a microscopy-based method that tags antibodies with a fluorescent dye), found IgM in about 50% of herpes zoster patients, which is better but still misses half of active cases. This low detection rate is why clinicians rarely rely on VZV IgM alone. It is one piece of evidence, not a standalone answer.

There is another wrinkle: VZV IgM cannot reliably distinguish a first-ever chickenpox infection from a shingles reactivation. IgM was found in 50% of herpes zoster patients, meaning the antibody appears in both scenarios. If you need to know whether your symptoms represent a new infection or a reactivation, this test alone will not tell you.

Ramsay Hunt Syndrome

One clinical setting where VZV IgM carries prognostic weight is Ramsay Hunt syndrome, a painful condition where VZV reactivates in the nerve near your ear, causing facial paralysis, hearing loss, and ear pain. In a study of 105 patients with this syndrome, those who tested positive for VZV IgM or IgG had more severe facial nerve damage and worse ear-related symptoms than those who were antibody-negative.

This finding may seem counterintuitive: you might expect a strong antibody response to mean better protection. But in this context, a positive IgM or IgG likely reflects a more intense viral flare, which triggers a bigger immune response alongside more nerve damage. The antibodies are a marker of how aggressively the virus is replicating, not a sign that your body is winning the fight.

VZV and Brain Infections

When VZV infects the brain (encephalitis), the primary diagnostic test is PCR (polymerase chain reaction, a technique that detects the virus's genetic material directly in spinal fluid). In a Danish nationwide study of 92 adults with VZV encephalitis, 93% were diagnosed by PCR, and only 7% by antibody testing. Serum VZV IgM plays a minor supporting role in this scenario.

Where antibody testing becomes more useful is later in the course of brain or eye infections, after the virus has stopped replicating and PCR may turn negative. In these cases, doctors can measure VZV IgG antibodies produced inside the spinal canal, which can pick up cases that PCR would miss. This is a different test from the serum VZV IgM you would order through a lab, but it is worth understanding the distinction.

VZV and Stroke Risk

Clinical episodes of shingles are linked to a temporary increase in stroke risk. Published meta-analyses pooling data from millions of patients have found that within three months of a shingles episode, the odds of a cardiac event may be roughly 30% higher than normal. For stroke specifically, risk may be roughly 50% or more higher in the first four weeks after shingles.

These associations are based on clinical shingles episodes, not on VZV IgM levels specifically. When researchers looked at past VZV antibody status (IgG positivity, meaning evidence of old infection), they found no consistent link with stroke. In other words, having had chickenpox decades ago does not appear to raise your stroke risk; a fresh reactivation event does. One small pediatric study found that VZV IgM positivity (indicating recent reactivation) was strongly associated with childhood stroke, but the evidence was graded low quality due to small sample size.

VZV and Dementia

A Korean nationwide study of over 752,000 adults found that people who had a clinical VZV infection were about 41% more likely to develop dementia over roughly 10 years of follow-up, after adjusting for age, sex, and cardiovascular conditions. A separate analysis of over 100 million US electronic health records found that shingles vaccination was associated with reduced dementia risk, and that the protection tracked with how well the vaccine prevented reactivation.

These findings again use clinical VZV events, not IgM titers (antibody concentration levels), as the exposure. No study has shown that a single positive VZV IgM result predicts long-term dementia risk in an individual. But the pattern is consistent: repeated or severe VZV reactivation appears to carry neurological consequences, and preventing reactivation (through vaccination or antiviral therapy) may offer protection.

How Results Are Reported

VZV IgM results are reported qualitatively: positive, negative, or equivocal. There are no universal numeric reference ranges. Each lab uses its own assay with manufacturer-specific cutoffs, so a "positive" in one lab might use a different threshold than another. This is one reason you should always compare results within the same lab if retesting.

Because labs use different assay platforms and cutoffs, a result from one lab is not directly comparable to a result from another. If you need to retest, use the same lab.

When Results Can Be Misleading

The biggest source of error with this test is timing. Draw blood too early (before day 6 after symptoms appear) and IgM may not have risen yet. Draw it too late (after 10 weeks) and IgM may have already disappeared. Both scenarios produce false negatives.

• Timing of blood draw: IgM becomes detectable about 6 to 10 days after rash onset and fades by roughly 10 weeks. Testing outside this window often produces a false negative.
• Immune suppression: People on chemotherapy, biologic drugs (such as daratumumab, which targets immune cells), JAK inhibitors (such as tofacitinib, which dampens immune signaling), or high-dose steroids may produce weaker or delayed antibody responses, making IgM less reliable.
• Assay differences: Different lab platforms (whole-virus ELISA versus glycoprotein-based ELISA) have different sensitivity and specificity. Switching between labs can create apparent changes that are really just measurement differences.
• Immunosuppressive medications that increase real reactivation risk: Drugs that block parts of the immune system, such as fingolimod (which traps immune cells in lymph nodes) and certain cancer therapies, increase the real risk of VZV reactivation. A positive IgM in someone on these drugs is more likely to represent true active infection rather than a false positive.

What a Positive Result Should Make You Do

A positive VZV IgM, especially with compatible symptoms (rash, nerve pain, facial weakness), should prompt immediate clinical evaluation. The first step is confirming the diagnosis with VZV IgG (to see if levels are rising, indicating active infection) and potentially VZV PCR if central nervous system or eye involvement is suspected.

If you have facial paralysis alongside a positive VZV IgM, evaluation by an ENT specialist or neurologist for Ramsay Hunt syndrome is warranted. If you have severe headache, confusion, or vision changes, cerebrospinal fluid testing (PCR and antibody index) should be pursued urgently.

A negative VZV IgM in someone with strong clinical suspicion for shingles or VZV-related disease should not end the investigation. Given the test's low sensitivity, your doctor may proceed with VZV PCR of a skin lesion or other specimen, paired serum IgG testing (two draws spaced 2 to 3 weeks apart to look for a rising titer), or clinical diagnosis based on the pattern of symptoms.

Why Retesting and Context Matter More Than a Single Result

This is not a biomarker you track over time like cholesterol or blood sugar. VZV IgM is a snapshot: either the virus is recently active, or it is not. A single negative result is only meaningful in the context of when it was drawn relative to symptoms. If your first test is negative but symptoms persist, a repeat draw 1 to 2 weeks later (paired with VZV IgG) can clarify the picture.

The most informative approach is pairing IgM with IgG at the same time point, then repeating IgG 2 to 3 weeks later. If IgG rises significantly between the two draws, that confirms recent active infection even if IgM was never detected. This paired-sample strategy compensates for IgM's poor sensitivity.

For people on immunosuppressive therapies where VZV reactivation risk is elevated, the relevant preventive action is not serial IgM monitoring. It is vaccination (with the recombinant shingles vaccine, which is made from a single viral protein rather than live virus) and, in some cases, preventive antiviral therapy. VZV IgG testing before starting immunosuppression confirms whether you have had prior exposure and are at risk for reactivation.